IP Library Granted Patent US 8,546,405
Granted Patent B2
US 8,546,405 · App. 12/644,432 · Granted Oct 1, 2013

Anti-viral compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,546,405
App. No.
12/644,432
Granted
Oct 1, 2013
Kind
B2
Abstract

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Claims (61)

1. A compound of Formula II, or a pharmaceutically acceptable salt thereof,

wherein:

X 1 and X 2 are each independently selected from a bond, -L S -, —O—, —S—, or —N(R B )—, and at least one of X 1 and X 2 is selected from —CH 2 —, —O—, —S—, or —N(R B )—;

R 7 and R 8 are each independently selected from hydrogen, -L A , C 5 -C 10 carbocyclyl, or 5- to 10-membered heterocyclyl, wherein at each occurrence said C 5 -C 10 carbocyclyl and 5- to 10-membered heterocyclyl are each independently optionally substituted with one or more R A ;

Z 1 and Z 2 are each independently selected from a bond, —C(R C R C′ )—, —O—, —S—, or —N(R B )—;

W 1 , W 2 , W 3 , W 4 , W 5 , and W 7 are each N, and W 6 and W 8 are each independently C(R D ), wherein R D is independently selected at each occurrence from hydrogen or R A ;

R 1 , R 2 , R 9 , R 11 , R 12 , R 14 , R 15 , and R 16 are each independently selected at each occurrence from hydrogen or R A ;

m and n are each independently selected from 0, 1, 2, or 3;

T is selected from a bond, -L S -, -L S -M-L S′ -, -L S -M-L S′ -M′-L S″ -, wherein M and M′ are each independently selected from a bond, —O—, —S—, —N(R B )—, —C(O)—, —S(O) 2 —, —S(O)—, —OS(O)—, —OS(O) 2 —, —S(O) 2 O—, —S(O)O—, —C(O)O—, —OC(O)—, —OC(O)O—, —C(O)N(R B )—, —N(R B )C(O)—, —N(R B )C(O)O—, —OC(O)N(R B )—, —N(R B )S(O)—, —N(R B )S(O) 2 —, —S(O)N(R B )—, —S(O) 2 N(R B )—, —C(O)N(R B )C(O)—, —N(R B )C(O)N(R B′ )—, —N(R B )SO 2 N(R B′ )—, —N(R B )S(O)N(R B′ )—, C 5 -C 10 carbocycle, or 5- to 10-membered heterocycle, and wherein T is optionally substituted with one or more R A ;

R A is independently selected at each occurrence from halogen, hydroxy, mercapto, amino, carboxy, nitro, phosphate, oxo, thioxo, formyl, cyano, -L A , or -L S -R E ;

R B and R B′ are each independently selected at each occurrence from hydrogen; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 -carbocyclyl, C 3 -C 6 carbocyclylC 1 -C 6 alkyl, 3- to 6-membered heterocyclyl, or (3- or 6-membered heterocyclyl)C 1 -C 6 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, phosphate, oxo, thioxo, formyl or cyano;

R C and R C′ are each independently selected at each occurrence from hydrogen; halogen; hydroxy; mercapto; amino; carboxy; nitro; phosphate; oxo; thioxo; formyl; cyano; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 3 -C 6 carbocyclyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, phosphate, oxo, thioxo, formyl or cyano;

L A is independently selected at each occurrence from C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —O—R S , —S—R S , —N(R S R S′ ), —OC(O)R S , —C(O)OR S , nitro, phosphate, oxo, thioxo, formyl or cyano;

L S , L S′ and L S″ are each independently selected at each occurrence from a bond; or C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —O—R S , —S—R S , —N(R S R S′ ), —OC(O)R S , —C(O)OR S , nitro, phosphate, oxo, thioxo, formyl or cyano;

R E is independently selected at each occurrence from —O—R S , —S—R S , —C(O)R S , —OC(O)R S , —C(O)OR S , —N(R S R S′ ), —S(O)R S , —SO 2 R S , —C(O)N(R S R S′ ), —N(R S )C(O)R S′ , —N(R S )C(O)N(R S′ R S″ ), —N(R S )SO 2 R S′ , —SO 2 N(R S R S′ ), —N(R S )SO 2 N(R S′ R S″ ), —N(R S )S(O)N(R S′ R S″ ), —OS(O)—R S , —OS(O) 2 —R S , —S(O) 2 OR S , —S(O)OR S , —OC(O)OR S , —N(R S )C(O)OR S′ , —OC(O)N(R S R S′ ), —N(R S )S(O)—R S′ , —S(O)N(R S R S′ ), —C(O)N(R S )C(O)—R S′ , C 3 -C 6 carbocyclyl, or 3- to 6-membered heterocyclyl, and said C 3 -C 6 carbocyclyl and 3- to 6-membered heterocyclyl are each independently optionally substituted at each occurrence with one or more substituents selected from R S (except hydrogen), halogen, —O—R B , —S—R B , —N(R B R B′ ), —OC(O)OR B , —C(O)OR B , nitro, phosphate, oxo, thioxo, formyl or cyano; and

R S , R S′ and R S″ are each independently selected at each occurrence from hydrogen; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 carbocyclyl, C 3 -C 6 carbocyclylC 1 -C 6 alkyl, 3- to 6-membered heterocyclyl, or (3- or 6-membered heterocyclyl)C 1 -C 6 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —O—R B , —S—R B , —N(R B R B′ ), —OC(O)R B , —C(O)OR B , nitro, phosphate, oxo, thioxo, formyl or cyano.

2. The compound or salt of claim 1 , wherein:

at least one of X 1 and X 2 is selected from —CH 2 —, —O—, or —S—;

at least one of R 7 and R 8 is selected from C 5 -C 6 carbocyclyl or 5- to 6-membered heterocyclyl, wherein said C 5 -C 6 carbocyclyl and 5- to 6-membered heterocyclyl are optionally substituted with one or more R A ; and

Z 1 and Z 2 are each independently —N(R B )—.

3. The compound or salt of claim 2 , wherein:

X 1 and X 2 are each independently selected from —CH 2 —, —O—, or —S—;

R 7 and R 8 are each independently selected from C 5 -C 6 carbocyclyl or 5- to 6-membered heterocyclyl, wherein at each occurrence said C 5 -C 6 carbocyclyl and 5- to 6-membered heterocyclyl are each optionally substituted with one or more R A ; and

Z 1 and Z 2 are each independently —N(R B )—.

4. The compound or salt of claim 1 , wherein:

R 1 and R 2 are hydrogen;

R 7 and R 8 are phenyl, and are each independently optionally substituted with one or more R A ; and

R 9 , R 11 , R 12 , R 14 , and R D are each independently selected at each occurrence from hydrogen; halogen; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 carbocyclyl, or C 3 -C 6 carbocyclyC 1 -C 6 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, phosphate, oxo, thioxo, formyl or cyano.

5. A compound of Formula III, or a pharmaceutically acceptable salt thereof,

wherein:

X 1 and X 2 are each independently selected from a bond, -L S -, —O—, —S—, or —N(R B )—, and at least one of X 1 and X 2 is selected from —CH 2 —, —O—, —S—, or —N(R B )—;

R 7 and R 8 are each independently selected from hydrogen, -L A , C 5 -C 10 carbocyclyl, or 5- to 10-membered heterocyclyl, wherein at each occurrence said C 5 -C 10 carbocyclyl and 5- to 10-membered heterocyclyl are each independently optionally substituted with one or more R A ;

Z 1 and Z 2 are each independently selected from a bond, —C(R C R C′ )—, —O—, —S—, or —N(R B )—;

W 1 , W 2 , W 3 , W 4 , W 5 , and W 7 are each N, and W 6 and W 8 are each independently C(R D ), wherein R D is independently selected at each occurrence from hydrogen or R A ;

R 1 , R 2 , R 9 , R 11 , R 12 , R 14 , R 15 , and R 16 are each independently selected at each occurrence from hydrogen or R A ;

m and n are each independently selected from 0, 1, 2, or 3;

T is selected from a bond, -L S -, -L S -M-L S′ -, -L S -M-L S′ -M′-L S″ -, wherein M and M′ are each independently selected from a bond, —O—, —S—, —N(R B )—, —C(O)—, —S(O) 2 —, —S(O)—, —OS(O)—, —OS(O) 2 —, —S(O) 2 O—, —S(O)O—, —C(O)O—, —OC(O)—, —OC(O)O—, —C(O)N(R B ) —, N(R B )C(O)—, —N(R B )C(O)O—, —OC(O)N(R B )—, —N(R B )S(O)—, —N(R B )S(O) 2 —, —S(O)N(R B )—, —S(O) 2 N(R B )—, —C(O)N(R B )C(O)—, —N(R B )C(O)N(R B′ )—, —N(R B )SO 2 N(R B′ ) —, —N(R B )S(O)N(R B′ ) —, C 5 -C 10 carbocycle, or 5- to 10-membered heterocycle, and wherein T is optionally substituted with one or more R A ;

R A is independently selected at each occurrence from halogen, hydroxy, mercapto, amino, carboxy, nitro, phosphate, oxo, thioxo, formyl, cyano, -L A , or -L S -R E ;

R B and R B′ are each independently selected at each occurrence from hydrogen; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 carbocyclyl, C 3 -C 6 carbocyclylC 1 -C 6 alkyl, 3- to 6-membered heterocyclyl, or (3- or 6-membered heterocyclyl)C 1 -C 6 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, phosphate, oxo, thioxo, formyl or cyano;

R C and R C′ are each independently selected at each occurrence from hydrogen; halogen; hydroxy; mercapto; amino; carboxy; nitro; phosphate; oxo; thioxo; formyl; cyano; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 3 -C 6 carbocyclyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, phosphate, oxo, thioxo, formyl or cyano;

L A is independently selected at each occurrence from C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —O—R S , —S—R S , —N(R S R S′ ), —OC(O)R S , —C(O)OR S , nitro, phosphate, oxo, thioxo, formyl or cyano;

L S , L S′ and L S″ are each independently selected at each occurrence from a bond; or C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —O—R S , —S—R S , —N(R S R S′ ), —OC(O)R S , —C(O)OR S , nitro, phosphate, oxo, thioxo, formyl or cyano;

R E is independently selected at each occurrence from —O—R S , —S—R S , —C(O)R S , —OC(O)R S , —C(O)OR S , —N(R S R S′ ), —S(O)R S , —SO 2 R S , —C(O)N(R S R S′ ), —N(R S )C(O)R S′ , —N(R S )C(O)N(R S′ R S″ ), —N(R S )SO 2 R S′ , —SO 2 N(R S R S′ ), —N(R S )SO 2 N(R S′ R S″ ), —N(R S )S(O)N(R S′ R S″ ), —OS(O)—R S , —OS(O) 2 —R S , —S(O) 2 OR S , —S(O)OR S , —OC(O)OR S , —N(R S )C(O)OR S′ , —OC(O)N(R S R S′ ), —N(R S )S(O)—R S′ , —S(O)N(R S R S′ ), —C(O)N(R S )C(O)—R S′ , C 3 -C 6 carbocyclyl, or 3- to 6-membered heterocyclyl, and said C 3 -C 6 carbocyclyl and 3- to 6-membered heterocyclyl are each independently optionally substituted at each occurrence with one or more substituents selected from R S (except hydrogen), halogen, —O—R B , —S—R B , —N(R B R B′ ), —OC(O)R B , —C(O)OR B , nitro, phosphate, oxo, thioxo, formyl or cyano; and

R S , R S′ and R S″ are each independently selected at each occurrence from hydrogen; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 carbocyclyl, C 3 -C 6 carbocyclylC 1 -C 6 alkyl, 3- to 6-membered heterocyclyl, or (3- to 6-membered heterocyclyl)C 1 -C 6 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —O—R B , —S—R B , —N(R B R B′ ), —OC(O)R B , —C(O)OR B , nitro, phosphate, oxo, thioxo, formyl or cyano.

6. The compound or salt of claim 5 , wherein:

at least one of X 1 and X 2 is selected from —CH 2 —, —O—, or —S—;

at least one of R 7 and R 8 is selected from C 5 -C 6 carbocyclyl or 5- to 6-membered heterocyclyl, wherein said C 5 -C 6 carbocyclyl and 5- to 6-membered heterocyclyl are optionally substituted with one or more R A ; and

Z 1 and Z 2 are each independently —N(R B )—.

7. The compound or salt of claim 5 , wherein:

X 1 and X 2 are each independently selected from —CH 2 —, —O—, or —S—;

R 7 and R 8 are each independently selected from C 5 -C 6 carbocyclyl or 5- to 6-membered heterocyclyl, wherein at each occurrence said C 5 -C 6 carbocyclyl and 5- to 6-membered heterocyclyl are each optionally substituted with one or more R A ; and

Z 1 and Z 2 are each independently —N(R B )—.

8. The compound or salt of claim 5 , wherein:

R 1 and R 2 are hydrogen;

R 7 and R 8 are phenyl, and are each independently optionally substituted with one or more R A ; and

R 9 , R 11 , R 12 , R 14 , and R D are each independently selected at each occurrence from hydrogen; halogen; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 carbocyclyl, or C 3 -C 6 carbocyclyC 1 -C 6 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, phosphate, oxo, thioxo, formyl or cyano.

9. A pharmaceutical composition comprising a compound or salt of claim 1 or 5 .

10. A process of making a compound of claim 1 or 5 , comprising the step of:

coupling a compound of Formula IV

to a compound of Formula V

wherein T 1 is a carboxylic acid, an activated derivative, or an activated ester and T 2 is an amine or a substituted amine, and A 1 , A 2 , Z 1 , Z 2 , W 1 , W 2 , W 3 , W 4 , R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined in claim 1 or 5 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030237/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2010
From: DEGOEY, DAVID A.; DONNER, PAMELA L.; KATI, WARREN M.; HUTCHINS, CHARLES W.; KRUEGER, ALLAN C.; RANDOLPH, JOHN T; MOTTER, CHRISTOPHER E.; KRISHNAN, PREETHI; MISTRY, NEETA C.; PILOT-MATIAS, TAMI J.; PATEL, SACHIN V.; LI, XIAOYAN; SOLTWEDEL, TODD N.; NELSON, LISSA T.
To: ABBOTT LABORATORIES
Reel/Frame 023902/0426 →